Updates are available Correction dated 2025-02-15

Article History

Received: 1 March 2024

Accepted: 22 April 2024

First Online: 12 June 2024

Change Date: 15 February 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00125-025-06372-z

Acknowledgements

: Some of the data were presented as an abstract at the 32nd Annual Symposium of the International Cannabinoid Research Society in 2022. Some of the figures were created using Servier Medical Art templates. We thank the Diabetes Unit of the Regional University Hospital of Malaga and the Endocrinology, Diabetes, Obesity, and Nutrition team at IBIMA-Plataforma BIONAND SSPA (Spain) (G. Rojo, R. El Bekay, S. Garcia Serrano, E. Garcia Escobar, A. Lago, C. Maldonado, A. Gentile, S. Hamyani, Juan M. Gomez Zumaquero) for their constant support and valuable input. We thank T. Diaz Cordoba, coordinator of the Andalusian Health System Biobank at IBIMA-Plataforma BIONAND (Spain) for her constant help. We thank the Biotherapy Platform at CHU of Lille (France) for the isolation of the islets from cadaveric donors used in this study and for their contribution to the evaluation of the islets. We thank B. Legendre at UMR1190, Inserm (France) and L. Antelo, M. J. Palomo and I. Mena at IBIMA-Plataforma BIONAND (Spain) for their support in the legal framework and management of the study. We thank the team at the animal facility of the University of Malaga (Spain), for contributing to the welfare of the animals used in this study.

: Transcriptomic analysis of sorted human beta cells are available at Gene Expression Omnibus database, accession no. GSE121863, available at . The data from the study in humans are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at IBIMA-Plataforma BIONAND and Inserm UMR1190, CHU of Lille.

: This study was funded by the Consejeria de Salud y Familias of Andalucía (PI-0318-2018), the project PID2021-128926OA-I00 was funded by MICIU/AEI/10.13039/501100011033 and UE, the Ministry of Science and Innovation (PID2021-128926OA-I00), the Spanish Diabetes Society (Sociedad Espanola de Diabetes, SED; CPC22133) and Agence Nationale de la Recherche (Laboratoire d’excellence European Genomic Institute for Diabetes under grant ANR-10-LABX-0046). IG-M and F-JB-S were funded by the Junta de Andalucía (Nicolas Monardes program; C1-0018-2019 and C-0070-2012, respectively). CIBERDEM is an initiative of the Instituto de Salud Carlos III, Madrid, Spain. JME was supported by the Intramural Research Program of the National Institute on Aging/NIH. IG-M was supported by Inserm.

: A patent application based on this work has been filed. IG-M, F-JB-S and MSRdA are the inventors of this patent. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: IG-M conceptualised and supervised the study and obtained funding. JME contributed to the conceptualisation of the study. EW, SH, VG, AC, MGD, LSS and IG-M performed experiments, and acquired, analysed and interpreted data. MSRdA, ICBE, MJVH, FL, F-JB-S, GO and NC acquired and/or analysed and/or interpreted data related to the clinical study. MC, GP, ND, JTh, CB, JK-C and FP acquired and/or analysed and/or interpreted data related to the human ex vivo study. SH contributed to the design and construction of CRISPR/Cas9 and AAVs, and LH and JTa acquired and/or analysed and/or interpreted data related to the lipidomic study. IG-M and EW performed the formal analysis. IG-M wrote the manuscript. All authors reviewed the article critically and approved the final manuscript. IG-M is the guarantor of this work.